Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Weekly Taxotere and Carboplatin in Advanced NSCLC
NCT00003562Phase 2Unknown
- Sponsor
- Hope Cancer Institute, Inc.
- Start
- Jul 1998
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and carboplatin in non-small cell lung cancer (NSCLC), sponsored by Hope Cancer Institute, Inc. Primary endpoint: Response Rate. Status: unknown.
02
Drugs
docetaxelcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00003562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003562.